🎉 M&A multiples are live!
Check it out!

BioXcel Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for BioXcel Therapeutics and similar public comparables like Vivoryon Therapeutics, Julphar, and Benevolent AI.

BioXcel Therapeutics Overview

About BioXcel Therapeutics

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.


Founded

2017

HQ

United States of America
Employees

37

Financials

LTM Revenue $2.4M

LTM EBITDA n/a

EV

$83.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

BioXcel Therapeutics Financials

BioXcel Therapeutics has a last 12-month revenue of $2.4M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, BioXcel Therapeutics achieved revenue of $2.3M and an EBITDA of -$44.2M.

BioXcel Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See BioXcel Therapeutics valuation multiples based on analyst estimates

BioXcel Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $1.4M $2.3M XXX XXX XXX
Gross Profit $0.4M $0.1M XXX XXX XXX
Gross Margin 26% 5% XXX XXX XXX
EBITDA -$165M -$44.2M XXX XXX XXX
EBITDA Margin -11987% -1949% XXX XXX XXX
Net Profit -$166M -$179M XXX XXX XXX
Net Margin -12011% -7902% XXX XXX XXX
Net Debt n/a $35.4M XXX XXX XXX

Financial data powered by Morningstar, Inc.

BioXcel Therapeutics Stock Performance

As of April 15, 2025, BioXcel Therapeutics's stock price is $2.

BioXcel Therapeutics has current market cap of $10.5M, and EV of $83.6M.

See BioXcel Therapeutics trading valuation data

BioXcel Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$83.6M $10.5M XXX XXX XXX XXX $-20.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

BioXcel Therapeutics Valuation Multiples

As of April 15, 2025, BioXcel Therapeutics has market cap of $10.5M and EV of $83.6M.

BioXcel Therapeutics's trades at 34.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate BioXcel Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for BioXcel Therapeutics and 10K+ public comps

BioXcel Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $83.6M XXX XXX XXX
EV/Revenue 36.9x XXX XXX XXX
EV/EBITDA -1.9x XXX XXX XXX
P/E -0.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioXcel Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

BioXcel Therapeutics Valuation Multiples

BioXcel Therapeutics's NTM/LTM revenue growth is 74%

BioXcel Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.8M for the same period.

Over next 12 months, BioXcel Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate BioXcel Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for BioXcel Therapeutics and other 10K+ public comps

BioXcel Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 64% XXX XXX XXX XXX
EBITDA Margin -1949% XXX XXX XXX XXX
EBITDA Growth -73% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1875% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.8M XXX XXX XXX XXX
S&M Expenses to Revenue 61% XXX XXX XXX XXX
G&A Expenses to Revenue 1461% XXX XXX XXX XXX
R&D Expenses to Revenue 1343% XXX XXX XXX XXX
Opex to Revenue 2865% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

BioXcel Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

BioXcel Therapeutics M&A and Investment Activity

BioXcel Therapeutics acquired  XXX companies to date.

Last acquisition by BioXcel Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . BioXcel Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by BioXcel Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About BioXcel Therapeutics

When was BioXcel Therapeutics founded? BioXcel Therapeutics was founded in 2017.
Where is BioXcel Therapeutics headquartered? BioXcel Therapeutics is headquartered in United States of America.
How many employees does BioXcel Therapeutics have? As of today, BioXcel Therapeutics has 37 employees.
Who is the CEO of BioXcel Therapeutics? BioXcel Therapeutics's CEO is Dr. Vimal Mehta, PhD.
Is BioXcel Therapeutics publicy listed? Yes, BioXcel Therapeutics is a public company listed on NAS.
What is the stock symbol of BioXcel Therapeutics? BioXcel Therapeutics trades under BTAI ticker.
When did BioXcel Therapeutics go public? BioXcel Therapeutics went public in 2018.
Who are competitors of BioXcel Therapeutics? Similar companies to BioXcel Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of BioXcel Therapeutics? BioXcel Therapeutics's current market cap is $10.5M
What is the current revenue of BioXcel Therapeutics? BioXcel Therapeutics's last 12-month revenue is $2.4M.
What is the current EV/Revenue multiple of BioXcel Therapeutics? Current revenue multiple of BioXcel Therapeutics is 34.3x.
What is the current revenue growth of BioXcel Therapeutics? BioXcel Therapeutics revenue growth between 2023 and 2024 was 64%.
Is BioXcel Therapeutics profitable? Yes, BioXcel Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.